Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
Go back to Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease| (NASDAQ: TARS) | Delayed: 63.56 +0.40 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.16 | 52 Week High | $ | |||
| Open | $63.34 | 52 Week Low | $ | |||
| Day High | $64.21 | P/E | N/A | |||
| Day Low | $62.51 | EPS | $ | |||
| Volume | 788,704 | |||||
